Holen Sie sich die Stockscreener-App
2.065
4.63%
-0.095
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
LXRX Stock Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
LXRX Stock Price, Quote & Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
Lexicon anticipates SONATA-HCM enrollment completion by mid-2026 while highlighting $100m Hercules debt facility - MSN
A Look At Lexicon Pharmaceuticals (LXRX) Valuation After Improved Q1 Revenue And Narrowed Net Loss - Sahm
Lexicon Pharmaceuticals: up to 50 percent of type 2 diabetes patients affected by painful neuropathy - Traders Union
Lexicon Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-05-15 - Seeking Alpha
Navigating Life with Hypertrophic Cardiomyopathy - GlobeNewswire Inc.
Lexicon Pharmaceuticals (LXRX) Is Up 52.5% After Q1 Loss Narrows And Revenue JumpsHas The Bull Case Changed? - simplywall.st
Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's Changed - Yahoo Finance
Lexicon Pharmaceuticals management to join Nasdaq HQ fireside chat - Traders Union
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - Herald and News
LXRX Maintained by Citigroup -- Price Target Raised to $3.10 - GuruFocus
$Lexicon Pharmaceuticals (LXRX.US)$ 🚀🚀🚀🚀🚀🤩🤩🤩🤩🤩 - Moomoo
Citigroup Issues Positive Forecast for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price - MarketBeat
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $3.1 - Moomoo
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones - Yahoo Finance
Lexicon Pharmaceuticals (LXRX) reports break-even earnings for Q1 - MSN
[SCHEDULE 13D/A] LEXICON PHARMACEUTICALS, INC. Amended Major Shareholder Report - Stock Titan
Major holder Artal group converts LXRX (LXRX) Series B preferred into 20.4M common shares - Stock Titan
5 Best Fast Growing Penny Stocks to Buy Right Now - Insider Monkey
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
LXRX SEC FilingsLexicon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Q1 2026 Lexicon Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Lexicon Pharmaceuticals: Buy Rating Reiterated as Value Catalysts Build; $6 Price Target Maintained - TipRanks
Lexicon Pharmaceuticals Q1 2026 earnings preview - MSN
Lexicon: Q1 Earnings Snapshot - theheraldreview.com
Lexicon Pharmaceuticals Q1 Earnings Call Highlights - Barchart.com
Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
LXRX Financials: Income Statement, Balance Sheet & Cash Flow | Lexicon Pharmaceuticals Inc - Stock Titan
Lexicon Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Lexicon Pharmaceuticals (NASDAQ: LXRX) Q1 2026 loss narrows on Novo milestones - Stock Titan
Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surge - Investing.com Nigeria
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1 - Yahoo Finance
LEXICON PHARMACEUTICALS ($LXRX) Releases Q1 2026 Earnings - Quiver Quantitative
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates - The Manila Times
Lexicon targets diabetes filing, heart trial, obesity study milestones - Stock Titan
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lexicon (NASDAQ: LXRX) Q1 2026 results, milestones and $100M loan - Stock Titan
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):